Same protocol, different continents, different patients: Should we continue to conduct global heart failure trials?

European Journal of Heart Failure

Volumn 17, Issue 9, 2015, Pages 875-878

  Greene, Stephen J ^a   Gheorghiade, Mihai ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COMORBIDITY; COST BENEFIT ANALYSIS; DEVELOPING COUNTRY; GEOGRAPHIC DISTRIBUTION; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HUMAN; PRIORITY JOURNAL; QUALITY CONTROL; REGISTER; REVIEW; SUDDEN CARDIAC DEATH; COST OF ILLNESS; DISEASE MANAGEMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC);

COST OF ILLNESS; DISEASE MANAGEMENT; HEART FAILURE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84941802131     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.335     Document Type: Review

References (16)

1. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316: 1429-1435.
2. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH,. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-1355.
3. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR,. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371: 993-1004.
4. Ahmad T, Pencina MJ, Schulte PJ, O'Brien E, Whellan DJ, Pina IL, Kitzman DW, Lee KL, O'Connor CM, Felker GM,. Clinical implications of chronic heart failure phenotypes defined by cluster analysis. J Am Coll Cardiol 2014; 64: 1765-1774.
5. Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, Bonow RO, Huang CC, Deo RC,. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 2015; 131: 269-279.
6. Greene SJ, Gheorghiade M,. Matching mechanism of death with mechanism of action: considerations for drug development for hospitalized heart failure. J Am Coll Cardiol 2014; 64: 1599-1601.
7. Ferreira JP, Girerd N, Rossignol P, Zannad F,. Geographic differences in heart failure trials. Eur J Heart Fail 2015.
8. Braunwald E., The war against heart failure: the Lancet lecture. Lancet 2015; 385: 812-824.
9. Pitt B, Gheorghiade M,. Geographic variation in heart failure trials: time for scepticism? Eur J Heart Fail. 2014; 16: 601-602.
10. Greene SJ, Shah AN, Butler J, Ambrosy AP, Anker SD, Chioncel O, Collins SP, Dinh W, Dunnmon PM, Fonarow GC, Lam CS, Mentz RJ, Pieske B, Roessig L, Rosano GM, Sato N, Vaduganathan M, Gheorghiade M,. Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. Am Heart J 2014; 168: 142-149.
11. Filippatos G, Khan SS, Ambrosy AP, Cleland JG, Collins SP, Lam CS, Angermann CE, Ertl G, Dahlstrom U, Hu D, Dickstein K, Perrone SV, Ghadanfar M, Bermann G, Noe A, Schweizer A, Maier T, Gheorghiade M,. International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. Eur J Heart Fail 2015; 17: 527-533.
12. Samman Tahhan A, Vaduganathan M, Kelkar A, Georgiopoulou VV, Kalogeropoulos AP, Greene SJ, Fonarow GC, Gheorghiade M, Butler J,. Trends in Heart Failure Clinical Trials from 2001 to 2012. J Card Fail; doi: 10.1016/j.cardfail.2015.06.014. Published online ahead of print 21 March 2015.
13. Frobert O, Lagerqvist B, Olivecrona GK, Omerovic E, Gudnason T, Maeng M, Aasa M, Angeras O, Calais F, Danielewicz M, Erlinge D, Hellsten L, Jensen U, Johansson AC, Karegren A, Nilsson J, Robertson L, Sandhall L, Sjogren I, Ostlund O, Harnek J, James SK,. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med 2013; 369: 1587-1597.
14. Hess CN, Rao SV, Kong DF, Aberle LH, Anstrom KJ, Gibson CM, Gilchrist IC, Jacobs AK, Jolly SS, Mehran R, Messenger JC, Newby LK, Waksman R, Krucoff MW,. Embedding a randomized clinical trial into an ongoing registry infrastructure: unique opportunities for efficiency in design of the Study of Access site For Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women). Am Heart J 2013; 166: 421-428.
15. Harinstein ME, Butler J, Greene SJ, Fonarow GC, Stockbridge NL, O'Connor CM, Pfeffer MA, Mehra MR, Solomon SD, Yancy CW, Fiuzat M, Mentz RJ, Collins SP, McMurray JJ, Vaduganathan M, Dunnmon PM, Rosano GM, Dinh W, Misselwitz F, Bonow RO, Gheorghiade M,. Site selection for heart failure clinical trials in the USA. Heart Fail Rev 2015; 20: 375-383.
16. Gheorghiade M, Bohm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A, Maggioni AP,. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 2013; 309: 1125-1135.